Eli Lilly, the maker of the popular weight loss injection Zepbound, is exploring other ways the drug can help people. In an interview with the Economic Club of Washington, D.C., this week, the company’s CEO, David Ricks, discussed the pharmaceutical giant’s plans for 2025.
“These medicines, we think, and we aim to prove, can be used for other things we don’t think about connected to weight,” Ricks said. “These are often called anti-hedonics, so they are reducing that desire cycle. So, next year you’ll see Lilly start large studies in alcohol abuse, in nicotine use, even in drug abuse.”
Point phone camera here
Zepbound is a GLP-1 drug. Those drugs work by mimicking hormones that make you feel satisfied after eating.
Researchers have known the mechanism in the brain that regulates food-seeking behaviors. They say it overlaps with the mechanism that regulates why some people develop addiction. However, Ricks said Eli Lilly’s upcoming study will be the first to test the use of these drugs specifically to treat addiction.
Zepbound started out under the name Mounjaro as a treatment for Type 2 diabetes. Eli Lilly later discovered patients could use Mounjaro’s active ingredient, tirzepatide, as an off-label prescription to encourage weight loss.
Shortly after, the Food and Drug Administration approved a version for weight loss purposes under the name Zepbound.
A new study by Loyola University released this week in the journal “Addiction,” found GLP-1 drugs show promise for treating drug and alcohol addiction.
Get up to speed on the stories leading the day every weekday morning. Sign up for the newsletter today!
By entering your email, you agree to the Terms & Conditions and acknowledge the Privacy Policy.
Researchers found people addicted to alcohol who also had a prescription for a GLP-1 drug had a 50% lower rate of binging alcohol. They also discovered people with opioid use disorder had a 40% lower rate of overdose.
Tags: Alcohol, Diabetes, Drugs, Eli Lilly, food, Health, Health Care, Men’s Health, Opioid Crisis, Overdose, Pharmaceutical, prescription drugs, Weight Loss, Women’s Health
[Craig]
ELI LILLY – THE MAKER OF POPULAR WEIGHT LOSS INJECTION ZEPBOUND – IS LOOKING AT OTHER WAYS THE DRUG CAN HELP PEOPLE.
[DAVID RICKS | CEO, ELI LILLY]
“These medicines, we think and we aim to prove, can be used for other things we don’t think about connected to weight. These are often called anti-hedonics, so they are reducing that desire cycle. So, next year you’ll see Lilly start large studies in alcohol abuse, in nicotine use, even in drug abuse.”
[Craig]
ZEPBOUND IS IN A GROUP OF DRUGS KNOWN AS G-L-P-1s THAT WORK BY MIMICKING HORMONES IN THE BODY THAT MAKE YOU FEEL SATISFIED AFTER EATING.
RESEARCHERS HAVE KNOWN FOR YEARS NOW THAT THE MECHANISM IN THE BRAIN THAT REGULATES FOOD-SEEKING BEHAVIORS OVERLAPS WITH THE MECHANISM THAT REGULATES WHY SOME PEOPLE DEVELOP ADDICTION… BUT ELI LILLY’S C-E-O SAYS ITS UPCOMING STUDY WILL BE THE FIRST TO TEST THE USE OF THESE DRUGS SPECIFICALLY TO TREAT ADDICTION.
ZEPBOUND STARTED OUT UNDER THE NAME MOUNJARO AS A TREATMENT FOR TYPE TWO DIABETES.
THEN IT WAS DISCOVERED MOUNJARO’S ACTIVE INGREDIENT – TIRZEPATIDE COULD BE USED OFF-LABEL TO ENCOURAGE WEIGHT LOSS AND IT WASN’T LONG BEFORE A VERSION WAS APPROVED FOR WEIGHT LOSS PURPOSES ONLY… UNDER THE NAME ZEPBOUND.
A NEW STUDY RELEASED THIS WEEK IN THE JOURNAL “ADDICTION” FOUND G-L-P-1 DRUGS SHOW PROMISE FOR TREATING DRUG AND ALCOHOL ADDICTION, AS WELL.
THE STUDY OUT OF LOYOLA UNIVERSITY FOUND PEOPLE WHO WERE ADDICTED TO ALCOHOL WHO ALSO HAD A PRESCRIPTION FOR A G-L-P-1 DRUG HAD A 50 PERCENT LOWER RATE OF BINGING ON ALCOHOL…
AND PEOPLE WITH OPIOID USE DISORDER HAD A 40 PERCENT LOWER RATE OF OVERDOSE.
FOR MORE OF THE HEALTH HEADLINES YOU CARE ABOUT – DOWNLOAD THE STRAIGHT ARROW NEWS APP TODAY.
Straight to your inbox.
By entering your email, you agree to the Terms & Conditions and acknowledge the Privacy Policy.
